- Home
- KOD vs VCEL Comparison
KOD vs VCEL Comparison
Compare KOD & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOD | VCEL |
|---|---|---|
| Founded | 2009 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | KOD | VCEL |
|---|---|---|
| Price | $23.63 | $32.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $28.29 | ★ $58.50 |
| AVG Volume (30 Days) | ★ 507.9K | 468.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.60 | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.09 |
| Revenue Next Year | N/A | $17.96 |
| P/E Ratio | ★ N/A | $101.67 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $1.92 | $29.24 |
| 52 Week High | $31.18 | $48.75 |
Technical Indicators
Market Signals| Indicator | KOD | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.71 | 34.45 |
| Support Level | $21.19 | $31.34 |
| Resistance Level | $26.21 | $38.48 |
| Average True Range (ATR) | 1.63 | 1.43 |
| MACD | -0.33 | -0.33 |
| Stochastic Oscillator | 19.66 | 15.61 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.